EPA ( DrugBank: - )
6 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 8 | ハンチントン病 | 6 |
| 46 | 悪性関節リウマチ | 4 |
| 48 | 原発性抗リン脂質抗体症候群 | 1 |
| 49 | 全身性エリテマトーデス | 2 |
| 113 | 筋ジストロフィー | 1 |
| 301 | 黄斑ジストロフィー | 1 |
8. ハンチントン病
臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-002088-98-PT (EUCTR) | 07/06/2006 | 16/03/2006 | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331 | Product Name: Ethyl-EPA Product Code: LAX-101 INN or Proposed INN: Ethyl Icosapent Other descriptive name: Ethyl-EPA | Amarin Neuroscience Ltd | NULL | Not Recruiting | Female: yes Male: yes | Portugal;Germany;United Kingdom;Spain;Italy | ||||
| 2 | EUCTR2005-002088-98-ES (EUCTR) | 29/12/2005 | 04/10/2005 | Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington. | Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington. | HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: llt;Classification code 10010331 | Product Name: Ethyl-EPA Product Code: LAX-101 | Amarin Neuroscience Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Portugal;Germany;United Kingdom;Spain;Italy | ||||
| 3 | EUCTR2005-002088-98-AT (EUCTR) | 01/12/2005 | 27/10/2005 | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331 | Product Name: Ethyl-EPA Product Code: LAX-101 INN or Proposed INN: Ethyl-Icosapent | Amarin Neuroscience Ltd | NULL | Not Recruiting | Female: yes Male: yes | 240 | Portugal;Spain;Austria;Germany;Italy;United Kingdom | |||
| 4 | EUCTR2005-002088-98-GB (EUCTR) | 07/11/2005 | 18/08/2005 | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331 | Product Name: Ethyl-EPA Product Code: LAX-101 | Amarin Neuroscience Ltd | NULL | Not Recruiting | Female: yes Male: yes | Portugal;Germany;United Kingdom;Spain;Italy | ||||
| 5 | NCT00146211 (ClinicalTrials.gov) | September 2005 | 2/9/2005 | TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease | A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease | Huntington Disease | Drug: Ethyl-EPA (Miraxion™) | Amarin Neuroscience Ltd | Huntington Study Group | Completed | 35 Years | N/A | Both | 300 | Phase 3 | United States;Canada |
| 6 | EUCTR2005-002088-98-DE (EUCTR) | 28/11/2006 | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | HUNTINGTON’S DISEASE MedDRA version: 8.0;Level: LLT;Classification code 10010331 | Product Name: Ethyl-EPA Product Code: LAX-101 INN or Proposed INN: Ethyl-Icosapent | Amarin Neuroscience Ltd | NULL | Not Recruiting | Female: yes Male: yes | 240 | Portugal;United Kingdom;Germany;Spain;Italy |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-016055-22-SE (EUCTR) | 09/03/2011 | 11/01/2011 | Hepatitis A vaccine in patients with immunomodulative drugs | Hepatitis A vaccine in patients with immunomodulative drugs | Patients with rheumatoid arthritis treated with immunosuppressive medication MedDRA version: 12.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis MedDRA version: 12.1;Classification code 10054980;Term: Immunosuppressant drug therapy MedDRA version: 12.1;Classification code 10063430;Term: Hepatitis A immunisation | Trade Name: Epaxal Product Name: Epaxal Other descriptive name: Inactivated hepatitis A virus Trade Name: Havrix Product Name: Havrix Other descriptive name: inactivated hepatitis A virus | HY, HUS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 380 | Finland;Sweden | |||
| 2 | NCT01274910 (ClinicalTrials.gov) | January 2011 | 4/1/2011 | Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial | Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial | Rheumatoid Arthritis | Dietary Supplement: EPAX 6000 EE 1000mg (0.6 gr DHA+EPA);Dietary Supplement: Capsules (Placebo) | Rabin Medical Center | NULL | Recruiting | 50 Years | 80 Years | Both | 60 | N/A | Israel |
| 3 | EUCTR2009-016055-22-FI (EUCTR) | 27/11/2009 | 09/10/2009 | Immuunipuutteisten matkailijoiden A-hepatiittisuojaus | Immuunipuutteisten matkailijoiden A-hepatiittisuojaus | Terveet vapaaehtoiset ja vapaaehtoiset potilaat, joilla on diagnosoitu nivelreuma. MedDRA version: 12.0;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Trade Name: Epaxal Product Name: Epaxal | HY, HUS | NULL | Not Recruiting | Female: yes Male: yes | Finland;Sweden | ||||
| 4 | NCT01360970 (ClinicalTrials.gov) | September 2009 | 24/5/2011 | Hepatitis A Vaccine in Patients With Immunomodulating Drugs | Hepatitis A Vaccination in Patients With Rheumatoid Arthritis Treated With TNF-inhibitors and/or Methotrexate | Response to Hepatitis A Vaccine | Biological: hepatitis A vaccine ( HAVRIX or EPAXAL) | Lars Rombo | NULL | Completed | 18 Years | N/A | Both | 68 | Phase 2 | Finland;Sweden |
48. 原発性抗リン脂質抗体症候群
臨床試験数 : 5 / 薬物数 : 6 - (DrugBank : 4) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01956188 (ClinicalTrials.gov) | May 2014 | 25/9/2013 | Omega 3 in LES and APS | Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome | Systemic Lupus Erythematosus;Primary Antiphospholipid Syndrome | Dietary Supplement: EPA and DHA supplementation;Dietary Supplement: Placebo | University of Sao Paulo | NULL | Active, not recruiting | 20 Years | 45 Years | Female | 22 | N/A | Brazil |
49. 全身性エリテマトーデス
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01956188 (ClinicalTrials.gov) | May 2014 | 25/9/2013 | Omega 3 in LES and APS | Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome | Systemic Lupus Erythematosus;Primary Antiphospholipid Syndrome | Dietary Supplement: EPA and DHA supplementation;Dietary Supplement: Placebo | University of Sao Paulo | NULL | Active, not recruiting | 20 Years | 45 Years | Female | 22 | N/A | Brazil |
| 2 | EUCTR2005-000706-31-IT (EUCTR) | 15/09/2005 | 30/09/2005 | A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients with Active Systemic LupusErythematosus | A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients with Active Systemic LupusErythematosus | improvement of signs and symptoms of Active Systemic Lupus Erythematosus MedDRA version: 8.1;Level: LLT;Classification code 10042945;Term: Systemic lupus erythematosus | Product Name: Epatuzumab Product Code: hLL2,IMMU-103 | IMMUNOMEDICS | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Germany;United Kingdom;Spain;Italy |
113. 筋ジストロフィー
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01826422 (ClinicalTrials.gov) | March 2013 | 4/4/2013 | Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients | Effect of Eicosapentaenoic Fatty Acid (EPA) and Docosahexaenoic Fatty Acids (DHA) Supplementation on the Inflammation State and Metabolic Disorders in Patients With Duchenne Muscular Dystrophy or Becker Muscular Dystrophy | Muscular Dystrophy, Duchenne | Dietary Supplement: EPA and DHA;Dietary Supplement: Placebo Comparator | Coordinación de Investigación en Salud, Mexico | Instituto Nacional de Rehabilitacion | Completed | 6 Years | 18 Years | Male | 40 | N/A | Mexico |
301. 黄斑ジストロフィー
臨床試験数 : 46 / 薬物数 : 42 - (DrugBank : 11) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00420602 (ClinicalTrials.gov) | September 21, 2007 | 10/1/2007 | DHA Supplementation in Patients With STGD3 | Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3 | Dominantly Inherited Stargardt's Disease (STGD3) | Dietary Supplement: Over the counter DHA/EPA dietary supplementation | University of Utah | NULL | Completed | 18 Years | 105 Years | All | 11 | N/A | United States |